Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
- 9 January 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 18 (4), 410-418
- https://doi.org/10.1016/s1473-3099(18)30002-1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort StudyCritical Care Medicine, 2017
- Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised studyThe Lancet Respiratory Medicine, 2017
- Middle East Respiratory SyndromeThe New England Journal of Medicine, 2017
- Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi ArabiaEmerging Infectious Diseases, 2016
- Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivoScience Translational Medicine, 2016
- The use of convalescent plasma to treat emerging infectious diseasesCurrent Opinion in Hematology, 2015
- Evaluation of candidate vaccine approaches for MERS-CoVNature Communications, 2015
- Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26Nature, 2013
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?Annals of Internal Medicine, 2006
- Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospitalJournal of Antimicrobial Chemotherapy, 2005